DTI 015

Drug Profile

DTI 015

Alternative Names: BCNU - Direct Therapeutics; Carmustine - Direct Therapeutics; Injectable carmustine - Direct Therapeutics

Latest Information Update: 26 Apr 2007

Price : $50

At a glance

  • Originator Direct Therapeutics
  • Class Antineoplastics; Nitrosourea compounds
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Glioblastoma; Liver cancer

Most Recent Events

  • 26 Apr 2007 Discontinued - Phase-I for Liver cancer in USA (Intratumoural)
  • 26 Apr 2007 Discontinued - Phase-II for Glioblastoma in USA (Intratumoural)
  • 24 Oct 2002 Approval to begin a new European study of DTI 015 in patients with newly diagnosed high-grade glioma has been granted by the United Kingdom's Medicines Control Agency
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top